New drug combo could make radioactive iodine work better for tough thyroid cancers
NCT ID NCT06440850
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests whether two targeted drugs, vemurafenib and cobimetinib, can help high-risk thyroid cancer patients respond better to standard radioactive iodine therapy. The drugs block a faulty protein that drives cancer growth, potentially making cancer cells more receptive to radiation. About 21 adults with a specific BRAF gene mutation will be enrolled and followed for around 14 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND PAPILLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.